- Home
- SNDL vs ACRS Comparison
SNDL vs ACRS Comparison
Compare SNDL & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDL | ACRS |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.0M | 311.0M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SNDL | ACRS |
|---|---|---|
| Price | $1.43 | $4.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $10.20 |
| AVG Volume (30 Days) | ★ 2.8M | 1.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $6.19 | N/A |
| Revenue Next Year | $3.08 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $1.22 |
| 52 Week High | $2.89 | $5.15 |
Technical Indicators
Market Signals| Indicator | SNDL | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 52.55 |
| Support Level | $1.31 | $4.08 |
| Resistance Level | $1.63 | $4.89 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 54.76 | 45.33 |
Price Performance
Historical ComparisonAbout SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.